Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
baseline in murine studies 60+ Publications On triple-agonist receptor compounds +31% Energy Expenditure Resting metabolic rate increase in models 28% Visceral Fat Intra-abdominal adipose reduction observed Mechanism of Action How GLP-3 (RT) Works Triple-receptor agonism the next generation of metabolic research GLP-1 Primary Glucagon-Like Peptide-1 Incretin hormone receptor activation Suppresses appetite via hypothalamic signaling Delays gastric emptying increases satiety Stimulates glucose-dependent insulin secretion GIP Co-agonist Glucose-Dependent Insulinotropic Polypeptide Adipose tissue and beta-cell modulation Enhances GLP-1 receptor potency synergistically Modulates fat cell lipid uptake and storage Supports pancreatic beta-cell preservation Glucagon Thermogenic Glucagon Receptor Component Hepatic glucose and energy expenditure Increases hepatic glucose output regulation Promotes brown adipose thermogenesis Elevates resting energy expenditure Research Applications Primary Research Areas Obesity & Adiposity Models Studied in diet-induced obesity (DIO) rodent models demonstrating significant reductions in body weight, fat mass, and food intake compared to single-agonist controls
Reputable compounding pharmacies are typically 503A or 503B registered facilities, and knowing which pharmacy is filling your order matters for quality assurance
Behavioral testing started once rats reached the 70 g/kg dose
Saxenda, a brand of the drug liraglutide, has been approved for use in the UK for certain groups of people with obesity meaning a BMI of 30 or greater or who are overweight with a BMI of 27 to 30 and have weight-related health problems
doi:10.1210/jc.2014-4235 12
